Introduction {#Sec1}
============

Uveitis is a sight-threatening eye disease inflicted by auto-immune disorders or infectious agents \[[@CR1]\]. Sarcoidosis is a multisystemic granulomatous chronic disorder with unknown etiology \[[@CR2], [@CR3]\]. In the eye this can cause uveitis with anterior chamber cells and flare, corneal deposits, synechiae formation, macular edema, vasculitis, retinitis, papillitis and/or a vitritis \[[@CR4]\]. Ocular manifestations of systemic sarcoidosis have significant impact on visual prognosis \[[@CR5], [@CR6]\]. Sarcoidosis patients with chronic disease often require prolonged treatment. Moreover, since sarcoidosis is a systemic disease, the effect of treatment on the various affected organs is important in deciding which therapy is the most appropriate. Regarding eye involvement, intermediate uveitis, posterior uveitis and panuveitis all require aggressive treatment regimen with immunosuppressive drugs in order to preserve vision and function of the eye \[[@CR6], [@CR7]\]. Corticosteroids remain the mainstay of treatment. However, in case this treatment does not have a favorable outcome or if disabling side-effects, which accompany prolonged treatment occur, use of other alternative, steroid-sparing agents is mandatory. Methotrexate has been proven to be a good alternative \[[@CR8]\]. In case this therapy also fails, use of biologic agents which block tumor necrosis factor-alpha (TNF-α) can provide effective treatment for the diverse manifestations of sarcoidosis \[[@CR9]--[@CR11]\]. Among the TNF-α inhibitors, infliximab has been studied most extensively in sarcoidosis \[[@CR9], [@CR11]--[@CR13]\]. Anti-TNF-α treatment has been efficacious for the treatment of refractory ocular inflammatory disease \[[@CR7], [@CR14]--[@CR18]\].

Adalimumab, a humanized monoclonal antibody targeted against TNF-α, has also been reported useful in treating uveitis, sarcoidosis and various other auto-immune disorders \[[@CR9], [@CR18]--[@CR26]\]. The aim of this prospective case series was to evaluate the effect of adalimumab on intraocular inflammatory signs and other relevant clinical manifestations (lung function, laboratory inflammatory parameters, and fatigue) in sarcoidosis patients with refractory chronic non-infectious uveitis.

Materials and methods {#Sec2}
=====================

All sarcoidosis patients referred to the sarcoidosis management team of the Maastricht University Medical Centre (MUMC), the Netherlands (a tertiary referral center), who started treatment with the anti-TNF-α drug adalimumab initiated by our ophthalmologist (RE) because of refractory posterior uveitis between March 2006 and December 2009 were followed systematically according to a clinical protocol for 12 months. Adalimumab was started based on the following clinical criteria: patients with refractory posterior uveitis who did not respond to the original therapy with immunosuppressive drugs (both prednisone and methotrexate;*n* = 20) and patients who responded to previous therapy with these immunosuppressive drugs, but demonstrated severe adverse effects (*n* = 6). It has to be emphasized that in order to prescribe the drug in the Netherlands for the treatment of uveitis, the patient had to be treated with at least two different immunosuppressive drugs, previously. Therefore, it is not allowed to use this drug as first choice in treating severe uveitis. Adalimumab was administrated at a dose of 40 mg subcutaneously once a week. Patients were instructed to inject themselves and to report side effects immediately. Only patients who were treated with adalimumab for at least six months and completed the follow-up period of 12 months were included in the analysis (*n* = 26).

The diagnosis sarcoidosis was based on consistent clinical features and bronchoalveolar lavage fluid analysis, in accordance with the WASOG guidelines with biopsy-proven noncaseating epithelioid cell granulomas confirming sarcoidosis in 21/26 (77%) patients \[[@CR27]\]. None of these patients had a relevant medical history or co-morbidity. At initial diagnosis, the presence of active tuberculosis was excluded. Just before initiating anti-TNF-alpha treatment a Quantiferon®- TB Gold in combination with the tuberculin skin test was repeated to exclude latent tuberculosis infection (LTBI) as this is a contraindication for treatment with TNF-α inhibitor therapy and also recommended in the guidelines of our hospital \[[@CR4], [@CR28]\]. At both time points, these tests were negative in all included patients.

Evaluation of clinical course {#Sec3}
-----------------------------

The different outcome measures were scored at baseline, 6 months and 12 months.

Evaluation of uveitis {#Sec4}
---------------------

All the patients were evaluated by the same ophthalmologist (RE). He screened the patients for the presence of uveitis on the following items. Using slit-lamp examination the eye was scrutinized on the presence of noduli in the conjunctival tissue; corneal deposits; anterior chamber cells and flare; anterior and posterior synechiae formation. These findings are not included because in our cases the anterior segment had no active signs of inflammation. In fact, 21 patients had no signs at all of uveitis anterior, while five patients had uveitis anterior in the past that showed no activity at the initial examination. Using funduscopy, the presence of macular edema, snowballs or vitreous opacities; multiple chorioretinal peripheral lesions; nodular and/or segmental periphlebitis and/or macroaneurysms or optic disc nodules were recorded. The Standardization of Uveitis Nomenclature (SUN) for clinical data was used in conjunction with the results of the first international workshop on the International Criteria for the Diagnosis of Ocular Sarcoidosis (IWOS) to score the location and activity of the uveitis \[[@CR4], [@CR29]\].

Additionally, fluorescein angiography (FA, Topcon, TRC-50 EX) or optical coherence tomography (OCT, Zeiss, Stratus model 3000) was performed in 20 patients to detect the presence of vasculitis, papillitis, or macular edema. In 16 cases, these findings were present bilateral. In total, three patients refused FA; in the remaining three cases it was thought that FA would have no beneficial effect.

The outcome of the specific inflammatory signs was scored as resolved if complete clearance of the specific inflammatory activity was seen; partial response if the specific inflammatory activity had decreased; stabilization if the specific inflammatory activity remained unchanged and deterioration if the specific inflammatory activity had increased.

Overall outcome of intraocular inflammatory signs was scored as improvement if at least one of the scored inflammatory signs showed a complete clearance in the absence of deterioration of other inflammatory signs; partial improvement if at least one of the scored inflammatory signs improved in the absence of deterioration of other inflammatory signs; stabilization if all inflammatory signs remained unchanged; deterioration if at least one of the inflammatory signs increased.

Pulmonary evaluation {#Sec5}
--------------------

Chest X-rays (CXR) were graded by one single person, blinded to the clinical data and according to the standard radiographic staging for sarcoidosis. According to the Scadding radiographic staging system, five stages of radiographical abnormality (0-IV) were recognized \[[@CR27]\]. The CXR stages of the included patients at the start of treatment with adalimumab were, respectively: 16 patients (62%) stage 0, four patients stage I (15%), four patients stage II (15%), and two patients (8%) stage III.

Lung function measurements, including forced vital capacity (FVC) were measured with a pneumotachograph (Masterlab, Jaeger, Würzburg, Germany). The diffusing capacity for carbon monoxide (DLCO) was measured by the single-breath method (Masterlab, Jaeger, Würzburg, Germany). Values were expressed as a percentage of predicted values. Lung function characteristics of the included patients are shown in Table [1](#Tab1){ref-type="table"}.Table 1Summary of relevant clinical characteristics of the studied sarcoidosis patients and the effect on clinical manifestations after 6 and 12 months of treatment with adalimumabTotal population; *n* = 26; baselineAfter 6 months treatment with adalimumabAfter 1 year treatment with adalimumab (*n* = 25)DLCO (% predicted ± SD) (normal \>80% of predicted)88 ± 1892 ± 1290 ± 15FVC (% predicted ± SD) (normal \>80% of predicted)97 ± 1594 ± 22102 ± 20CRP (mean ± SD) (2--9 μg·ml^-1^)4.8 ± 5.32.4 ± 2.6\*3.6 ± 4.4\*ACE (mean ± SD) (9--25 U·L^-1^)19 ± 814 ± 9\*15 ± 10sIL-2R (mean ± SD) (240--3154 pg·ml^-1^)2803 ± 22241888 ± 1537\*2188 ± 1801\*FAS (mean ± SD) (\<22: no fatigue)31.1 ± 11.128.5 ± 7.8\*28.9 ± 10.0\**n*: number;*SD* standard deviation;*DLCO* diffusion capacity for carbon monoxide;*FVC* forced vital capacity;*CRP* C-reactive protein;*ACE* serum angiotensin-converting enzyme;*sIL-2R* soluble interleukin-2 Receptor;*FAS* Fatigue Assessment Scale\**p* \< 0.01 compared with baseline

Laboratory assays {#Sec6}
-----------------

The C-reactive protein (CRP) concentration and serum levels of angiotensin converting enzyme (ACE) and soluble interleukin-2 receptor (sIL-2R) were measured as described in a previous study of our group \[[@CR30]\].

Fatigue questionnaire {#Sec7}
---------------------

The Fatigue Assessment Scale (FAS) is a ten-item questionnaire to asses fatigue. Five questions reflecting physical fatigue and five questions assessing mental fatigue \[[@CR31]\].

The response scale is a five-point scale (1 never to 5 always); scores on the FAS can range from 10 to 50. The cut-off score of the FAS was 22. A score below 22 indicates no fatigue, whereas a score of 22 or higher indicates fatigue.

Statistical procedure {#Sec8}
---------------------

Differences between results at baseline, 6 months and 12 months were tested for statistical significance using the paired t test in case of continuous variables or Chi-square test in case of categorical variables. Statistical analyses were performed using SPSS, version 15.0 for Windows (SPSS Inc., Chicago, IL, USA). A *p*-value less than 0.05 was considered statistical significant.

Results {#Sec9}
=======

Relevant baseline clinical characteristics of the patients are shown in Table [1](#Tab1){ref-type="table"}. The details on uveitis manifestations at baseline are included in Table [2](#Tab2){ref-type="table"}. Mean age was 51 ± 15 years, nine patients were male. Before adalimumab was initiated all patients were treated with oral corticosteroids (starting dose 20--60 mg daily), if this did not have a positive effect, MTX was added (12.5--15 mg once a week orally). In eight cases, no MTX was added due to earlier reported side-effects. One patient (number 16 in Table [2](#Tab2){ref-type="table"}) was previously treated with infliximab, however, she developed antibodies after 2 years of treatment. To reduce side-effects of treatment, adjunctive therapy in the studied population (*n* = 26) was tapered during treatment with adalimumab: prednisone from 15.6 ± 10.7 to 3.6 ± 5.0 (*p* \< 0.01) and MTX from 9.6 ± 5.5 to 5.6 ± 4.1 (*p* \< 0.05), respectively. The dosages of these drugs could be tapered gradually within the first 6 months of treatment with adalimumab. Thereafter, all patients remained on the same (lower) dosage. After tapering, adjunctive therapy consisted of only oral corticosteroids in four patients (5--10 mg daily); corticosteroids together with methotrexate (MTX) in six (mean dose MTX 8.6 ± 4.4; range 5--15 mg daily), and MTX alone in 12 patients (mean dose 7.6 ± 2.4; range 5--12.5 mg once a week orally). Four patients did not use adjunctive therapy.Table 2Ocular manifestations of uveitis at baseline and after 6 months of treatment with adalimumabPatientSex ageInvolved Eye OD/OSPAP OD start/6 mPAP OS start/6 mMAC OD start/6 mMAC OS start/6 mCHO OD start/6 mCHO OS start/6 mVAS OD start/6 mVAS OS start/6 mVIT OD start/6 mVIT OS start/6 m1F 440/11/01/02F 340/11/1-3M 561/11/01/04F 731/11/01/05F 641/11/01/01/01/06F 401/11/01/07F 581/11/01/1-8F 791/11/01/01/01/09F 471/11/1-1/1-1/01/010F 351/01/01/011F 411/11/01/01/01/012M 691/11/1-1/1-13F 591/11/01/014M 671/11/01/015M 331/11/1-1/1-1/1-1/1-16F 560/11/017F 790/11/1-1/1-18M 461/11/01/01/01/019F 390/11/020M 431/11/01/021F 371/01/022F 231/11/01/01/01/023F 490/11/024M 641/11/01/01/1-1/1-25M 631/01/026M 411/01/0*F* female;*M* male;*OD* right eye;*OS* left eye;*m* months;*NLP* no light perception;*PAP* papillitis;*MAC* macular edema;*CHO* choroidal involvement;*VAS* vasculitis;*VIT* corpus vitreous cells;*1* present or yes;*0* absent or no;*-* partial improvement

Table [2](#Tab2){ref-type="table"} provides the details on the intraocular inflammatory signs after 6 months of treatment with adalimumab. The results after 12 months of treatment with adalimumab are not shown in Table [2](#Tab2){ref-type="table"} for viewing purposes, since in none of the patients the results regarding intraocular inflammatory signs changed between 6 and 12 months. Papillitis (the presence of inflammatory disc swelling) was present in eight patients and resolved in seven patients (no staining on FA), one had partial response (less staining on FA). Eight patients had macular involvement, this resolved in five of them (no leakage on FA or OCT) and a partial response was seen in three patients (less leakage). An example of resolved macular edema after treatment is shown in Fig. [1](#Fig1){ref-type="fig"}. Choroidal involvement was present in 15 patients and resolved in ten (clearance of inflammatory activity on funduscopy) whereas five had a partial response. Vasculitis resolved in the one patient (no leakage on FA as shown in Fig. [2](#Fig2){ref-type="fig"}). All of the five patients with vitreous involvement showed a clearing of the vitreous of at least two steps on fundus examination. The final outcome regarding intraocular inflammatory signs showed improvement in 22 patients (85%) and stabilization in four patients (15%).Fig. 1Optical coherence tomography (*top*) and fluorescein angiography (*bottom*) of OS showing macula edema before (*left*) and after (*right*) starting with adalimumabFig. 2Patient 11: Fluorescein angiography showing vasculitis before (*top*) and after (*bottom*) starting with adalimumab

Patient number 22 developed bilateral glaucoma prior to the start of adalimumab treatment, partly due to prednisone therapy, and was successfully treated with a glaucoma surgery procedure OD (Baerveldt implant) after eight months of adalimumab treatment. This procedure was performed successfully during adalimumab therapy and no activation was seen postoperatively.

Table [1](#Tab1){ref-type="table"} displays the effect on clinical manifestations after six and twelve months of treatment with adalimumab. Inflammatory parameters demonstrated a positive reaction during the anti-TNF-α treatment with adalimumab; the sIL-2R increased in three of 26 patients and decreased or stayed within normal limits in 23, whereas the ACE increased in two patients and decreased or stayed within normal limits in 24 of the 26. CRP levels at baseline were elevated in seven patients. Only one patient had as slightly elevated CRP level after 6 months (14 mg/ml), whereas after 12 months in all patients the CRP level was within the normal range. Mean levels of CRP, ACE, and sIL-2R decreased significantly during treatment with adalimumab.

None of the patients had an abnormal FVC (\<80% of the predicted value); eight patients appeared to have a decreased diffusing capacity (DLCO \< 80% of the predicted value) at baseline. After 6 months of treatment, seven of eight patients demonstrated an improvement of at least 10%, whereas one patient remained stable. This increase in DLCO in patients with a decreased TLCO was significant (*p* \< 0.01) and still present after 1 year of treatment.

Most of the patients (*n* = 21; 81%) suffered from fatigue (FAS score ≥22), whereas 11 (42%) suffered from very severe fatigue (FAS score \>35). Fourteen of these 21 patients (67%) became less fatigued, four (19%) remained stable, and three (14%) reported a minor increase of their fatigue problems, as depicted by the FAS. The FAS score decreased significantly during treatment with adalimumab (*p* \< 0.01; Table [1](#Tab1){ref-type="table"}).

Only one patient showed any signs of serious adverse effects during adalimumab treatment. This patient (number 16) developed a severe side effect at the injection site which led to the formation of a solid subcutaneous mass. However, because of the favorable effect on the uveitis she wanted to continue the treatment. Over time, this effect on the skin decreased but was still present after 12 months of treatment. Minor adverse effects, such as local skin reactions occurred in four patients. These minor adverse effects tapered off during the treatment period. All but one patient continued treatment with adalimumab during the follow-up period of 1 year. This one patient decided by herself to discontinue the adalimumab after a period of seven months into the treatment, although no side-effects had occurred.

Discussion {#Sec10}
==========

In this prospective case series of sarcoidosis patients with refractory chronic non-infectious posterior uveitis, adalimumab treatment appeared successful. For it not only showed an improvement of the intraocular inflammatory signs in the majority of patients (85%), but also appeared to have a significantly positive effect on other sarcoidosis related features, including inflammatory parameters, diffusing capacity, and fatigue. Until the endpoint of the evaluation (December 2010), no deteriorations were reported in those successfully treated. Serious adverse effects only occurred in one patient.

The presence of posterior uveitis is a predictor of a poor visual prognosis, making treatment with immunosuppressive drugs mandatory \[[@CR6], [@CR8]\]. All patients in our case series had uncontrolled inflammation due to prednisone and methotrexate resistance or intolerance, or a flare-up during treatment, and therefore ocular inflammation after 12 months of follow-up would have been expected to be worse without attempting a different therapy like with adalimumab. Intraocular inflammatory signs at baseline were modest in some of the included patients. However, in the past they had posterior uveitis which again showed a flare-up, also with respect to the serological inflammatory signs, despite treatment. Delay in effective treatment could lead to refractory inflammation, potentially leading to further damage in the eye. Given the fact that further therapeutic options were limited in these cases, early adjunctive treatment was indicated. Furthermore, six of the included patients responded to previous therapy with immunosuppressive drugs, but demonstrated severe adverse effects. Therefore, also in these patients, the intraocular inflammatory signs were not pronounced.

If visually disabling cataract formation or glaucoma develops in patients with uveitis, it is essential that no ocular inflammatory activity is present at the time of surgery \[[@CR32]\]. One of our patients was successfully treated with a glaucoma surgery procedure (Baerveldt implant) during adalimumab therapy and no activation was seen postoperatively.

Disabling side-effects of steroid treatment, including cataract formation, glaucoma, osteoporosis, Cushing's syndrome or diabetes mellitus, and the refractory character of the uveitis in some sarcoidosis patients, stress the need for alternatives. In the patients of this case series, adalimumab appeared to be a well-tolerated alternative and the dosage of both prednisone and MTX could be tapered down significantly during this treatment.

Previously, adalimumab also appeared to be an appropriate alternative for infliximab in patients with Crohn's disease who first responded quite well, but had to stop due to antibody formation and/or the development of an allergic reaction and became intolerant to infliximab \[[@CR33]\]. The decision to switch to another TNF-α inhibitor has not been studied systematically in sarcoidosis. However, switching from infliximab to adalimumab has been successful for some patients in case of allergic reactions \[[@CR34]\]. In our institute, we successfully switched therapy in five patients (including patient 16 of the present study) whom had formed antibodies against infliximab (data not shown).

Previously, the combination of anti-TNF-α therapy and a cytotoxic drug has been shown to be superior to anti-TNF-α therapy alone \[[@CR35]\]. However, this was not reported in all situations \[[@CR36], [@CR37]\]. In our patients, the immunosuppressive medication as taken at the start of anti-TNF-α therapy was continued unless side effects occurred or contra-indications existed. In those cases the dosage of the MTX and prednisone was tapered off as described in the results section.

It remains unclear how long anti-TNF-α therapy in a responding patient should be continued. In sarcoidosis, longer follow-up data are needed to determine the optimal treatment period to avoid disease relapse or deterioration. In our experience, treatment should be continued for at least a year instead of a shorter period as in rheumatoid arthritis.

A recent randomized controlled trial with infliximab versus placebo in chronic pulmonary sarcoidosis patients showed a change in FVC, the primary end point of that study \[[@CR12]\]. Although in our studied population none of the patients had a decreased FVC (\<80% of predicted), eight showed a decreased diffusing capacity (\<80% of predicted) at baseline. These latter patients demonstrated a significant improvement of the DLCO after 6 months and 1 year of treatment with adalimumab. Unfortunately, the DLCO was not evaluated in the previously mentioned infliximab study \[[@CR12]\].

Several reports suggest that CRP can predict response to anti-TNF-α therapy in different inflammatory diseases \[[@CR38]--[@CR42]\]. In line with this, in the present study, a decrease of the CRP was demonstrated after 6 months as well as after 1 year of treatment with adalimumab. Also, the decrease in ACE and sIL2-R and the improvement of fatigue during treatment with adalimumab is in accordance with findings of previous studies with anti-TNF-α agents, mainly infliximab, in sarcoidosis patients \[[@CR11], [@CR43]\]. Thus, although the primary reason for initiating treatment with adalimumab was refractory uveitis, the treatment also resulted in the improvement of systemic (inflammatory) manifestations of sarcoidosis.

This study has several limitations. Since during the follow-up period every sarcoidosis patient with refractory chronic non-infectious uveitis (as defined previously) in our clinic was treated with adalimumab in the absence of contra-indications, no control group could be evaluated. Also, the clinical examiner was not masked in grading response to treatment.

In conclusion, in this case series of sarcoidosis patients with refractory chronic non-infectious posterior uveitis, adalimumab appeared to be successful by showing improvement of intraocular inflammatory signs. Moreover, other relevant clinical indicators of disease activity improved as well. Future randomized studies are needed to determine optimal dosage, dose interval, and duration of therapy in refractory multisystemic sarcoidosis.
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